Decision pages for men already holding an MRI, PI-RADS category, biopsy result or pathology term.
A PI-RADS 2 MRI is considered low suspicion, but a persistently high PSA can still justify further risk assessment. The MRI lowers concern; it does not make the rest of the evidence disappear.
PI-RADS 3 means the lesion is indeterminate for clinically significant prostate cancer. Biopsy is not automatic, and monitoring is not automatically safe either.
A PI-RADS 3 lesion combined with PSA density around 0.15 is often treated as a more consequential risk profile than the MRI category alone.
Family history can raise baseline prostate-cancer risk, which means the same PI-RADS 3 lesion may lead to a different discussion in different men.
A prior negative biopsy lowers risk but does not make a later PI-RADS 3 finding irrelevant. The value of repeat biopsy depends on what was sampled before and what has changed.
PI-RADS 4 indicates high suspicion for clinically significant prostate cancer. Tissue sampling is commonly discussed because MRI alone cannot establish pathology.
PI-RADS 5 is the highest MRI suspicion category. Biopsy is generally central to establishing diagnosis, grade and treatment planning.
A negative MRI and a high PSA density pull risk assessment in opposite directions. That conflict often keeps biopsy or closer surveillance on the table.
A negative prostate MRI can support monitoring in some men, but others still have enough residual risk to justify biopsy.
Multiparametric MRI before a first biopsy can identify suspicious targets, estimate prostate volume and sometimes help avoid unnecessary biopsy in lower-risk scenarios.
MRI is especially useful before repeat biopsy because it can identify lesions missed by prior systematic sampling and help direct targeted cores.
Targeted biopsy samples MRI-visible lesions, while systematic biopsy samples predefined areas across the gland. Many biopsy strategies use both.
MRI-ultrasound fusion uses software to map an MRI target onto live ultrasound. Cognitive targeting relies on the operator mentally translating MRI location during ultrasound-guided biopsy.
Traditional TRUS-guided systematic biopsy samples the prostate under ultrasound guidance without requiring an MRI target. MRI-fusion biopsy adds targeted sampling of suspicious lesions.
Transperineal biopsy passes needles through the perineal skin; transrectal biopsy passes through the rectal wall. Both can be used for systematic or targeted sampling.
Recovery after transperineal biopsy commonly includes temporary soreness, blood in urine or semen and short-term urinary symptoms.
Passing biopsy needles through the rectum creates a different infection-risk profile than a transperineal approach. This is one reason biopsy route has become an important decision point.
Anticoagulants and antiplatelet drugs can affect bleeding risk around biopsy. Medication changes must be coordinated with the clinician managing the drug.
Antibiotic strategy differs by biopsy route, local resistance patterns and patient risk. Transperineal approaches generally have lower infectious risk than transrectal sampling.
A negative biopsy does not fully resolve a persistent PI-RADS 4 lesion. Sampling error, targeting quality and pathology review become important questions.
A PI-RADS 5 lesion with negative biopsy is a high-discordance scenario that usually deserves careful review rather than automatic reassurance.
Repeat biopsy after a negative fusion biopsy is not automatic. It depends on PSA behavior, MRI evolution, PSA density and confidence that the target was sampled correctly.
MRI and transrectal ultrasound can produce different prostate-volume estimates because of imaging planes, gland shape and measurement technique.
Gleason 3+3=6 corresponds to Grade Group 1 and is generally considered low-grade prostate cancer. Many men are candidates for active surveillance depending on stage, PSA and tumor volume.
Both scores total 7, but 3+4 is Grade Group 2 and 4+3 is Grade Group 3. The predominant pattern is more aggressive in 4+3 disease.
Grade Group 1 and Grade Group 2 differ mainly by the presence of Gleason pattern 4 in Grade Group 2. That can change surveillance versus treatment discussions.
High-grade prostatic intraepithelial neoplasia is not invasive prostate cancer. Whether repeat biopsy is needed depends on how extensive the finding is and what PSA/MRI show.
Atypical small acinar proliferation means the pathologist saw suspicious glands that were insufficient for a definitive cancer diagnosis.
Cribriform architecture is an adverse histologic feature in prostate cancer and can influence risk interpretation and treatment discussions.
Perineural invasion means prostate-cancer cells are seen tracking around or along a nerve within the biopsy specimen. Its significance depends on the rest of the pathology and clinical stage.
